In a recent pre-clinical trial, a novel replication-defective recombinant adenovirus 40 (rAd40) expressing mouse mesothelin (Msln) was administrated intravenously in mouse models as a prophylactic cancer vaccine against metastatic lesions of pancreatic cancer. The gene discussed is MSLN; the disease is pancreatic neoplasm.